BusinessKura Oncology Announces Issuance of U.S. Patent for Lead Product Candidate Tipifarnib in Head and Neck CancerBy Nasdaq OMXJul 18, 2017, 11:30 AM UTC
BusinessKura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS Mutant Head and Neck CancerBy Nasdaq OMXJul 13, 2017, 11:30 AM UTC
BusinessKura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell LymphomaBy Nasdaq OMXJun 14, 2017, 11:30 AM UTC
BusinessAdamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 WeeksBy Nasdaq OMXJun 8, 2017, 8:10 PM UTC
BusinessKura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual MeetingBy Nasdaq OMXJun 7, 2017, 11:30 AM UTC
BusinessKura Oncology to Participate in Two Upcoming Investor ConferencesBy Nasdaq OMXMay 30, 2017, 11:33 AM UTC
BusinessKura Oncology to Participate in Two Upcoming Investor ConferencesBy Nasdaq OMXMay 30, 2017, 11:33 AM UTC
BusinessKura Oncology to Participate in Two Upcoming Investor ConferencesBy Nasdaq OMXMay 30, 2017, 11:33 AM UTC
